Syndax Pharmaceuticals Inc
NASDAQ:SNDX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.36
24.81
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SNDX stock under the Base Case scenario is 16.2972 USD. Compared to the current market price of 16.0679 USD, Syndax Pharmaceuticals Inc is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Syndax Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SNDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Syndax Pharmaceuticals Inc
Balance Sheet Decomposition
Syndax Pharmaceuticals Inc
Current Assets | 414.8m |
Cash & Short-Term Investments | 406.4m |
Receivables | 4.7m |
Other Current Assets | 3.7m |
Non-Current Assets | 11m |
Long-Term Investments | 10m |
PP&E | 756k |
Other Non-Current Assets | 217k |
Current Liabilities | 59.4m |
Accounts Payable | 4.9m |
Accrued Liabilities | 49m |
Other Current Liabilities | 5.5m |
Non-Current Liabilities | 2k |
Long-Term Debt | 2k |
Earnings Waterfall
Syndax Pharmaceuticals Inc
Revenue
|
16m
USD
|
Operating Expenses
|
-337.2m
USD
|
Operating Income
|
-321.2m
USD
|
Other Expenses
|
24.2m
USD
|
Net Income
|
-297.1m
USD
|
Free Cash Flow Analysis
Syndax Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
SNDX Profitability Score
Profitability Due Diligence
Syndax Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Syndax Pharmaceuticals Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
SNDX Solvency Score
Solvency Due Diligence
Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Score
Syndax Pharmaceuticals Inc's solvency score is 88/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SNDX Price Targets Summary
Syndax Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for SNDX is 37.1123 USD with a low forecast of 18.18 USD and a high forecast of 53.55 USD.
Dividends
Current shareholder yield for SNDX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SNDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, engages in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2016-03-03. The Company’s lead product candidates include SNDX-5613 and SNDX-6352 (axatilimab). The firm is focused on developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1), protein for the treatment of MLL-rearranged (MLLr), acute leukemias and nucleophosmin 1 (NPM1), mutant acute myeloid leukemia (AML), as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. The Company’s products candidate also includes entinostat, once-weekly, oral, small molecule and Class I histone deacetylases (HDAC) inhibitor that being evaluated in the Phase III E2112 registrational clinical trial in combination with exemestane for hormone receptor positive, human epidermal growth factor receptor 2 negative and breast cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one SNDX stock under the Base Case scenario is 16.2972 USD.
Compared to the current market price of 16.0679 USD, Syndax Pharmaceuticals Inc is Undervalued by 1%.